Health
17 Oct 2026
City Therapeutics Raises $200 Million IPO to Fund RNAi Drugs Beyond the Liver
The biotech sold 11.1 million shares at $18 each, raising $200 million to push its RNA interference pipeline beyond liver‑targeted therapies.
Read moreTopic
#Stargardt disease
1 story